
Please try another search
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China. The company’s core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors. It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase I clinical trial to treat solid tumors; IMM2520, which is in Phase I clinical trial for solid tumors; and IMM47 for the treatment of advanced malignant and solid tumors, and R/R B-NHL. In addition, the company develops IMC-002 for treating autoimmune indications; IMC-001 for the treatment of atherosclerosis; IMM72; IMM7211b; IMM51, IMM38, IMM50, and IMM62 for solid tumors; and IMM40H for liquid/solid tumors. It has license and collaboration agreement with Instil Bio, Inc. for the development of IMM2510 and IMM27M. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was incorporated in 2015 and is headquartered in Shanghai, China.
Name | Age | Since | Title |
---|---|---|---|
Song Li | 39 | 2015 | VP of Research & Development and Executive Director |
Mei Guan | 42 | 2022 | Joint Company Secretary, VP of the Financing & Investment Strategy Department and Executive Director |
Zhenping Zhu | 60 | 2016 | Independent Non-Executive Director |
Ruliang Zhang | 40 | 2017 | Deputy GM, Senior VP & Executive Director |
Chi Tat Yeung | 56 | 2022 | Independent Non-Executive Director |
Cong Xu | 40 | 2020 | Non-Executive Director |
Zimeng Zhao | 33 | 2022 | Employee Representative Supervisor |
Miao Tian | 32 | 2017 | Chairman of Supervisory Committee |
Kendall Arthur Smith | 82 | 2022 | Independent Non-Executive Director |
Dawei Fu | - | 2025 | Non-Executive Director |
Wei Zhang | 36 | 2024 | Employee Representative Supervisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review